Tibolone: A Unique Version of Hormone Replacement Therapy

@article{Swegle2004TiboloneAU,
  title={Tibolone: A Unique Version of Hormone Replacement Therapy},
  author={J. Swegle and M. Kelly},
  journal={Annals of Pharmacotherapy},
  year={2004},
  volume={38},
  pages={874 - 881}
}
OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, and safety of tibolone in the treatment of menopausal symptoms and the prevention of osteoporosis. DATA SOURCES Information was obtained from a MEDLINE search (1966–July 2003) and from Organon International. The bibliographies of reviewed literature were searched for additional studies. STUDY SELECTION AND DATA EXTRACTION Studies and review articles evaluating tibolone were evaluated. Since tibolone has been available for many… Expand
Tibolone as Hormonal Therapy and Neuroprotective Agent
TLDR
It is suggested that TIB is a hormonal therapy with promising neuroprotective properties that can improve mood and cognition, neuroinflammation, and reactive gliosis in the brain. Expand
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg
TLDR
Estradiol 0.5 mg/norethisterone acetate 0.1 mg, despite being a lower dose than conventional hormones, is a compound, among a few other low-dose options, that can be used in hormone replacement therapy, and has demonstrated its effectiveness, with high tolerability and, apparently, no safety concerns, in a 6-month study. Expand
Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches
TLDR
In postmenopausal headache sufferers, analgesics are more effective in alleviating severe head pain when women are treated with T in comparison with low-dose EPT for climacteric complaints. Expand
'Tib the balance': the search for the optimal hormone replacement therapy.
This editorial refers to ‘Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy’† by Y.T. van der SchouwExpand
Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer
TLDR
There is strong epidemiological, experimental and clinical evidence that the etiology of breast cancer is closely related to long-term exposure of breast epithelium to sex steroid hormones, and these new HRT modalities could have different impact on breast cancer risk because of their metabolic and pharmacodynamic effects. Expand
Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.
  • A. Rapkin
  • Medicine
  • American journal of obstetrics and gynecology
  • 2007
TLDR
The availability of centrally active therapies for menopausal vasomotor symptoms with risks and benefits clearly defined by results from well-designed clinical trials has the potential to allay safety concerns that are associated with the treatment of these common symptoms. Expand
Sex hormones and related compounds, including hormonal contraceptives
TLDR
This chapter discusses sex hormones and related compounds including hormonal contraceptives, and Diethylstilbestrol has clearly been shown to cause primary vaginal carcinoma in the second generation and tumors continue to occur in women in middle age. Expand
Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy
TLDR
This guidance regarding estrogen-based hormone replacement therapy (HRT), including tibolone, which is classified in the British National Formulary as HRT, responds to the results and analysis of the randomized Women's Health Initiative studies and the observational Million Women Study. Expand
Tibolone protects T98G cells from glucose deprivation
TLDR
It is suggested that glial cells may participate in the neuroprotective actions of Tibolone in the brain and decrease the effects of glucose deprivation on cell death, nuclear fragmentation, superoxide ion production, mitochondrial membrane potential, cytoplasmic calcium concentration and morphological parameters. Expand
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide Cell kinetic and electron microscopical studies with a broad review of the literature
TLDR
Investigation of interactions between MPA, tibolone and temozolomide in modification of glioma cell growth and fine structure revealed synergisms that involved mitochondrial proliferation, condensation, mitophagy and autophagy. Expand
...
1
2
...

References

SHOWING 1-10 OF 40 REFERENCES
Tibolone for postmenopausal women: systematic review of randomized trials.
TLDR
The results from the randomized, controlled, and double blind trials of tibolone are discussed, with respect to its effects on climacteric symptoms, sexual function, endometrial and breast tissue, lipid metabolism, and bone mineral density. Expand
Pharmacokinetics of tibolone in early and late postmenopausal women.
TLDR
The pharmacokinetics of tibolone are similar in early (age 45-55 years) and late (65-75 years) postmenopausal women and the two formulations were bioequivalent with respect to the dose-normalized AUC (0, infinity) and the AUC(0,t(fix) values for the 3alpha- and 3beta-hydroxy t Tibolone. Expand
Tibolone: a steroid with a tissue-specific mode of action
  • H. Kloosterboer
  • Medicine, Biology
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2001
TLDR
It is concluded that tibolone acts as a tissue-specific compound by mediating its effects via steroid receptors and enzymatic pathways, and avoids stimulation of the endometrium and breast tissue. Expand
Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
TLDR
Tibolone provides an efficient and safe means of treating the postmenopausal syndrome in every‐day practice and significantly relieved all of the classical menopausal complaints. Expand
The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women.
TLDR
It is seen that tibolone with acceptable androgenic side effects can be an appropriate selection for HRT in postmenopausal women with decreased sexual desire and subjective well being. Expand
Effects of tibolone on the breast.
TLDR
In postmenopausal women oestroprogestogenic replacement therapy may be associated with an increase in mammographic density and with the onset or increase in mastodynia and may be considered a first-rate replacement therapy in case of mammas showing particular density or benign mastopathies. Expand
Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.
TLDR
Tibolone seems to offer a complete treatment of the climacteric complaints whilst avoiding some of the problems associated with classical hormone replacement therapy. Expand
Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause.
TLDR
Tibolone is as effective or more than 17 beta-estradiol in reducing climacteric symptoms, and shows greater triglyceride and total cholesterol improvements, and is a good alternative to estrogens in women with surgical menopause. Expand
Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
TLDR
An increase in mammographic density should be regarded as an unwanted side effect of hormone replacement therapy, in contrast to estrogen/progestogen treatment. Expand
Effects of tibolone on plasma homocysteine levels in postmenopausal women.
TLDR
Despite the reported beneficial effect of tIBolone on the serum lipid profile, tibolone had no statistically significant effect on serum homocysteine levels in postmenopausal women. Expand
...
1
2
3
4
...